
Real-world data is an invaluable supplement to randomised control trials
11 June 2020
- An article was published recently in the Journal of Clinical Pathways, titled “Real-World Data Will Continue to Provide Real Value to the Drug Development and Commercialization Process”
- It affirmed that while randomised controlled trials provide the necessary information on drug safety and efficacy, they are often not generalisable to the real-world population; but real-world information can supplement this data gap
- The paper proposes that real-world evidence may become vital to the drug development landscape as it allows for “creative and nimble” data collection and analysis that can provide the information demanded by precision medicine and/or small patient populations
Click here to learn more
About SVMPharma
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com
ref: JUN2020LN001